Pharma: Other News To Note
Wednesday, April 24, 2013
Sucampo Pharmaceuticals Inc., of Bethesda, Md., said the FDA approved its prostone-based therapy Amitiza (lubiprostone) as the first oral treatment of opioid-induced constipation (OIC) in patients with chronic, noncancer pain.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.